1. Scrip
  2. >>Therapy Areas
  3. >>Anti-infective

FDA notes increased risk of intussusception with Rotarix

 
• By Nancy Faigen

The US FDA said that preliminary results from a post-marketing study in Mexico involving GlaxoSmithKline's rotavirus vaccine, Rotarix, suggests a small increased risk of the bowel abnormality intussusception in the 31 day period after the first dose, and that these interim results can now be found in the US label for the product under "Warnings and Precautions". Information has also been added to the postmarketing experience section.

The US FDA said that preliminary results from a post-marketing study in Mexico involving GlaxoSmithKline's rotavirus vaccine, Rotarix, suggests a small increased risk of the bowel abnormality intussusception in the 31 day period after the first dose, and that these interim results can now be found in the US label for the product under "Warnings and Precautions". Information has also been added to the postmarketing experience section.

An interim analysis of the Mexican study on Rotarix suggests that there is an increased risk for intussusception in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anti-infective

In Brief: BioVersys And Shionogi Align In Non-Tuberculous Mycobacteria R&D

 
• By Joseph Haas

Deal Snapshot: Having recently raised an $89m IPO, BioVersys is partnering on and optioning rights to a preclinical NTM development program with Shionogi.

Moderna Posts Phase III Efficacy Data For Flu Vaccine

 
• By Joseph Haas

With positive relative efficacy data for its mRNA seasonal flu shot, Moderna hopes to file mRNA-1010 for US approval and refile a COVID-19/flu combo shot that it withdrew in May.

GSK, Bharat On Shigella Vaccine Phase II Data Timelines, Malaria Vaccine Price Halving

 
• By Vibha Ravi

GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut

Industry’s Vaccines Pipeline In A Changing Regulatory Landscape

 
• By Jessica Merrill

More than a dozen vaccines for infectious diseases are in Phase III development across the industry, as the US regulatory environment brings increased uncertainty.

More from Therapeutic Category

BerGenBio Plumps For Oncoinvent From Long List Of 50 Suitors

 
• By Kevin Grogan

The merger with a fellow Norwegian biotech comes a few months after its lead asset, bemcentinib, bit the dust.

In Brief: Opus Gears Up For FDA Filing In Presbyopia

 
• By Sushmita Panda

Data from a second pivotal trial support a filing in the US for Opus Genetics’ phentolamine ophthalmic solution, to treat presbyopia.

Protagonist Hopes To Come From Behind In Obesity With Oral Triple Agonist

 
• By Jessica Merrill

The company announced plans to move an oral GLP-1/GIP/GCG receptor agonist peptide into clinical development for obesity in 2026.